InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.33
(
-0.32%
)
Bitcoin
61,028.56
(
0.41%
)
Post# of 30387
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Headache

Send PM Follow Ignore
Followers 1
Posts 313
Boards Moderated 0
Alias Born 06/16/2005

Headache

Re: bocxman post# 2212

Thursday, 02/16/2006 12:11:44 PM

Thursday, February 16, 2006 12:11:44 PM

Post# of 30387
Bocxman, re. your statement: "In my opinion the biggest risk to this investment is not failure of RECAF, but instead, the clinical indication that Abbott chooses to pursue."

How much leeway does Abbott have in terms of choosing an indication? I must admit, I'm getting a bit confused about this. Can Abbott really select any indication they want?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up